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11.1 INTRODUCTION
According to the World Health Organization’s
report, the world population is rapidly aging. The
average life expectancy is increasing worldwide and
the ratio of the older population (i.e., persons 65 years
or older) to the overall population has gotten larger.
The number of people over 60 years is expected to
increase from 605 million, an estimation made in 2000,
to two billion by 2050, and the percentage of the aged
population will have doubled from 11 to 22% [1]. With
this rise in average lifespan there is a surge in the
amount of age-related cognitive deficits as well as
age-associated diseases. This can interfere with an
independent lifestyle for the elderly, as well as put a
burden on potential caregivers. For instance, the preva-
lence of age-related dementia, which is a progressive
brain disorder, increases with age. There are no
definitive therapies against dementia, and informal
and formal care cause a burden on society, families,
and caregivers for the elderly [2]. Thus, finding
appropriate interventions that alter the course of
aging-related disorders is quite important.
Aging is defined as a normal physiological process
in which gradual deterioration in body functions
occurs [3]. Gradual declines in sensory, motor,
and cognitive functions are accompanied with brain
aging [4]. With the growing number of older people,
aging-associated cognitive decline, which is related to
cognitive impairments, has become an important issue.
A significant loss of learning and memory capacity,
decline in visual and hearing abilities, some gastroin-
testinal tract problems, motor deficits, deterioration of
balance control, and fall-related injuries are several
clinical problems in the elderly population associated
with the aging of the nervous system [5]. Beyond these
clinical manifestations, age-related cognitive decline is
associated with cognitive dysfunctions, reduced self-
sufficiency and loss of independence, which reduce
quality of life for older adults [6]. Cognitive capacity
decreases during the process of aging even in the
absence of a diagnosed pathology. It is a result
of multifactorial changes which are combinations of
genetic and environmental etiologies [7]. Dissecting
the effects of individual factors and revealing the
molecular, cellular, and cognitive mechanisms are
important in terms of devising restorative interven-
tions for age-related cognitive decline.
In this chapter, we will first provide data on the
course of normal versus pathological aging. We will
then consider the role of mammalian target of
rapamycin (mTOR) signaling in aging, neurological
and non-neurological diseases. Taken together, the
available data suggest that mTOR signaling may
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underlie the cellular and molecular changes with
aging. The potential for factors such as the mTOR
pathway to impact those aging-related behavioral and
molecular changes, as well as possible interventions,
also are considered.
11.2 COGNITIVE ALTERATIONS
ASSOCIATED WITH NORMAL AGING
Normal aging is associated with behavioral and
cognitive alterations. However, these changes in age-
related cognitive capacities are a multidimensional
process; decline across one cognitive domain may not
be in parallel with or indicative of a falling-off that
would occur in another domain. Therefore, some
cognitive abilities may decrease at older age but
some cognitive skills are preserved.
The pattern of age-related cognitive decline and
alterations differs between pathological and normal
aging. Therefore, during the analysis of age-related
cognitive decline, considering these two directions of
normal versus pathological aging is important
(Table 11.1). Cognitive decline and alterations in
behavior can occur in attention, learning, memory,
and executive functions, as well as language abilities.
However, the most common and significant declines
are usually observed in the learning and memory
domains, whose deficiency affects and reduces the
well-being of older adults [8]. Therefore, focusing on
specific components of these two cognitive domains
including episodic memory, semantic memory, and
spatial learning-memory will be important for helping
elderly individuals maintain their independence.
Episodic memory is memory for autobiographical
events and its retrieval depends on contextual or
temporal cues [9] and performance on tasks utilizing
this ability declines with normal aging [10,11]. In,
addition to poor episodic memory abilities during
older ages, functional magnetic resonance imaging
studies revealed that older adults show a different pat-
tern of hippocampal formation and parahippocampal
activity during the episodic memory tasks when they
are compared with the young control group, and
these age-related alterations in the hippocampal
and parahippocampal activities may play a role
in the age-related decline in episodic memory [12]
(Figures 11.1 and 11.2). In the pathological aging
conditions, people show a larger decline than normal
aging groups in terms of episodic memory. Older
people with mild cognitive impairment [13] and
people with Alzheimer’s disease (AD) show poorer
performance in episodic memory tasks than their
healthy old group counterparts [9]. In terms of neural
activity, older people with AD show a more
widespread and decreased activity than the healthy
older group, with observations of changes in the
posterior cingulate and hippocampal formation [14].
These activity alterations could account for the
performance differences between normal and patho-
logical aging.
Semantic memory, which is referred to as acquired
knowledge and concepts independent from contextual
cues like the meaning of the words and geographical
facts, is another component of memory [9]. Unlike the
episodic component of the memory domain, age-
related cognitive decline is not so evident in semantic
memory [15]. Experimental evidence suggests that
there may be some decline but it is not necessarily a
linear one since it is has been shown that 55- to
60-year-old people tend to show better performance in
semantic memory tasks than the younger and older
controls [11]. Also, in terms of brain activity, neural
activity dedifferentiation found in episodic memory
tasks is not found in semantic memory tasks between
old and young groups, which indicates that the course
of activation required for semantic memory is similar
between young and old groups [16]. Therefore, based
on these findings it could be concluded that semantic
memory is preserved during normal aging. On the
other hand, in the pathological aging conditions like
AD, this preserved pattern is not observed and there is
an evident decline in semantic memory [17]. The
differences in performance in semantic memory tasks
between AD and normal aging are likely explained by
the volume loss in left medial perirhinal cortex,
entorhinal cortex, and hippocampal formation [18].
Spatial learning and memory are components of the
learning and memory domains in which particular
locations are associated with distinct stimuli or cues,
and these stimuli are used to learn the location of the
object of interest. This process requires both learning
and memory abilities [19]. In different animal models
[2023] and human studies [24,25], it has been demon-
strated that the performance related to spatial learning
and memory reduces with normal aging. Older groups
tend to show poor spatial learning and memory ability
when they are compared with young groups in related
tasks including the radial maze, Morris water maze,
virtual maze, and so forth. It has been suggested that
age-related deficits in spatial memory are associated
with hippocampal integrity and during aging as
hippocampal function declines, spatial learning and
memory deficits begin to occur [20,23]. In terms of
comparisons between normal and pathological aging
conditions, it has been shown that older people with
Lewy body dementia and AD tend to show worse
performance in spatial learning and memory-related
tasks when compared to healthy old groups, and
people with Lewy body dementia tend to show more
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TABLE 11.1 Summary of the Molecular, Cellular, and Behavioral Findings Associated with Cognitive Deficits, and Effects of mTOR
Manipulations in Normal and Pathological Brain Ageing Conditions
Findings -
Neural loss Molecular alterations Behavioral alterations
Effects of mTOR
manipulationsConditions k
Normal aging No neural loss Subtle changes in
synaptic integrity
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cognitive deficits in spatial memory than people with
AD [26]. Therefore, although some cognitive abilities
decline with normal aging, this impairment becomes
more severe during pathological aging.
11.3 CELLULAR AND MOLECULAR
ALTERATIONS ASSOCIATED WITH
NORMAL BRAIN AGING
Determining the cellular and molecular changes
that are occurring in the aging brain and underlie
cognitive decline is key to determining the targets for
possible interventions. Early studies suggested that
age-related cognitive decline is a result of significant
cell [27,28] and synapse loss [29,30], but subsequent
studies using unbiased counting techniques have
shown that overall loss of cells [3133] and synapse
[34,35] associated with aging was not observed.
Instead, it has been proposed that subtle changes in
synaptic integrity rather than large-scale alterations are
likely to underlie age-related cognitive decline [7].
For example, there is an age-related decline in
axospinous-type synapses in the dentate gyrus of the
hippocampus, a structure that is integrally linked to
learning and memory [30,36]. In the hippocampus,
Smith et al. reported no changes in synaptophysin
levels, a key synaptic protein, between young and old
rats, however, when the aged animals were separated
according to their memory ability, they found
decreases in synaptophysin levels for behaviorally
impaired old rats in the molecular layer of the dentate
gyrus and the lacunosum-moleculare layer of CA3 [37]
(Figure 11.2). Thus, unlike pathological aging that is
associated with a disease state, it is likely that there
are very subtle region- and layer-specific age-related
changes in synapses during normal aging, suggesting
the importance of examining other aspects of synapses
which may also be changing with age.
Multiple factors may be affecting the function of syn-
apses in the aging brain. For example, brain-derived
neurotrophic factor (BDNF), which is a neurotrophin
family member and a mediator of synaptogenesis,
synaptic plasticity, neuronal survival, and differentia-
tion in the mammalian brain [38,39] is another factor
that is related to cognitive aging. Age-related learning
impairments were reported in a study which used a
heterozygous BDNF knockout mouse model [40].
Neurogenesis, which is a process required for
maintenance of cellular turnover and cognitive plastic-
ity in adult brains, was shown to decrease dramatically
in the subventricular zone (SVZ) of the forebrain lateral
ventricles of old rodents. SVZ is the main source of
neural stem cells. The major decline was detected
during the transition from young age to middle
age [41]. Since newborn granule cells are proposed to
be involved in pattern separation [42], drastic decreases
in neurogenesis at old age might be related to cognitive
decline from this aspect [43]. The endocannabinoid
system functions in neuroprotection, regulation of neu-
rogenesis, and BDNF expression [43,44]. This system is
FIGURE 11.2 Hippocampus and parahippocampal gyrus. A
schematic diagram showing the hippocampal regions CA1, CA2/
CA3, CA4, dentate gyrus, entorhinal and perirhinal cortices
(parahippocampal gyrus). CA1, CA3, dentate gyrus, entorhinal and
perirhinal cortices are affected regions both in normal and
pathological aging conditions, and their aberrant functioning is likely
to underlie learning and memory deficits in the elderly.
FIGURE 11.1 Human brain medial view. A schematic drawing
illustrating the medial view of the human brain. Hippocampus,
found in the medial temporal lobe and cingulate gyrus, positioned in
parts of the frontal and parietal lobes, are highlighted. In this view,
the anterior part of the brain is towards the left and the posterior to
the right.
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involved in the aging process and indeed mutant mice
lacking cannabinoid 1 (CB1) receptor performed much
worse in several learning and memory tests as aging
progressed [45,46]. These findings indicated an acceler-
ated cognitive aging phenotype associated with the
deletion of the CB1 receptor gene, and further research
proposed an age-related function for CB1 receptor on
cortical glutamatergic neurons in habituation and
acquisition of spatial learning [44].
In terms of gene expression profiles that are altered
with increasing age, the most affected gene expression
profiles are those whose functions are involved in
calcium signaling and the cyclic adenosine monopho-
sphate response element-binding protein pathway [47],
synaptic plasticity, mitochondrial function, stress
response, DNA repair, and inflammation [48,49].
A gene expression study in which young and old male
and female zebrafish brains were compared found that
neurogenesis, cell differentiation, and development
of brain- and nervous-system-related genes are
differentially expressed [50]. Epigenetic regulations
depending on histone modifications are also associated
with the aging process [51,52]. Since changes in
the chromatin structure lead to outcomes at the
transcriptional level, they may result in alterations of
the hippocampal gene expression and eventually may
impair cognitive functions [53]. Alterations in the
expression of genes that function in inflammation
and apoptosis are accelerated in neurodegenerative
diseases [43].
A key molecular target that may contribute to
age-related cognitive decline is the glutamate receptor.
Glutamate receptors are the primary mediators of excit-
atory transmission in the central nervous system [54],
and play an important role in learning and memory,
connecting them to age-related decline [55,56]. In the
adult hippocampus, the primary types of glutamate
receptors are N-methyl-D-aspartate (NMDA) and
alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid (AMPA). Each of the pharmacologically defined
classes of ionotropic glutamate receptors are composed
of multimeric assemblies of protein subunits [54].
The critical subunits for NMDA receptors are NR1,
NR2A, and NR2B, and for AMPA receptors are GluR1
and GluR2. Families of subunits are recognized by
sequence homology [54,57,58] and supported by copre-
cipitation studies revealing distinct subunit assembly
patterns [59,60], and common electrophysiological and
pharmacological properties demonstrated in expression
systems [54,61,62]. Finally, glutamate receptors have
been linked to learning and memory such that
decreases in levels lead to memory impairments [63]
and increases lead to memory enhancement [64].
Glutamate receptors, in particular the NMDA
receptor, have been implicated in age-related cognitive
decline [6567]. Age-related changes in glutamate
receptor levels have been observed in many studies,
although the data are equivocal as to the direction of
change. Although age-related decreases in NMDA
receptor levels, specifically in NR1 and NR2B, have
been described in some studies [68,69], there are
studies with contradictory results that show no changes
[70]. Additionally, age-related decreases in the AMPA
receptor subunits GluR1 and GluR2 levels have been
reported in all the subfields of the rat hippocampus
[71]. In addition to the molecular alterations, functional
changes in excitatory transmission mediated by
glutamate receptors have been reported in the aging
hippocampus. For example, long-term potentiation
(LTP), an NMDA receptor-dependent plasticity
mechanism, and a model of cellular learning and
memory, has been shown to have a faster rate of decay
in aged animals [65]. The threshold for induction of
LTP is elevated in aged rats [72], and the late phase
of LTP has been found to be significantly reduced in
aged mice [23]. Moreover, there is a shift in LTP from
being an NMDA-dependent mechanism to one that is
dependent on voltage-dependent Ca21 channels in
hippocampal CA1 of aged rats [73]. Additionally, there
is a significant reduction in both NMDA and
non-NMDA glutamate receptor-mediated excitatory
postsynaptic potentials in CA1 of 27-month-old rats
as compared to 9-month-old rats [74]. Finally, the mag-
nitude of LTP is reduced in the aged animals [68,69].
Thus, these data suggest that glutamate receptor
changes, particularly NMDA receptors, may contribute
to age-related declines in cognitive function.
In the brain, the astroglia interact very closely with
glutamatergic synapses forming what is called the
tripartite synapse. It is becoming clear that astroglia
play a very important role in synaptic transmission in
addition to their role as a trophic support for neurons.
They integrate and process synaptic information and
control synaptic transmission and plasticity [75]. While
the primary focus of aging-related research has been
on alterations in excitatory synapses that contribute to
age-related cognitive decline, very little work has been
done on the contribution of glial changes during aging
and our knowledge is rudimentary at best. It is well
established that as there are changes in excitatory
synapses, there are parallel changes in glial cells. For
example during the estrous cycle there are fluctuations
in the circulating levels of estrogen. In the rodent
hippocampus, it is well-documented that excitatory
synapse number increases when estrogen levels are
high [76]. Moreover, there is evidence that as the
number of these excitatory synapses increases and
decreases, the number of astrocytic processes increases
and decreases in a concomitant manner [77,78]. In the
context of aging, there is evidence suggesting that glial
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fibrillary acidic protein (GFAP)-positive astrocytes
become fewer, smaller and less complex in the CA1
region of the hippocampus [79]. The level of glutamine
synthetase, which is an enzyme that is critical for
glutamate homeostasis and is maintained by astrocytes
to help neurons produce glutamate, is reduced in the
hippocampus but the levels of S100β, a calcium-
binding protein that regulates astrocytic movement
and shape, is increased in the aged brain [80]. Beside
these findings, our knowledge of glial modifications in
the context of aging is still very limited. The
age-related changes in glia are more complex than
expected, thus, they should be further investigated in
relation to alterations in excitatory synapses. Thus,
while some of the observations of cellular and molecular
changes in the normal aging brain may be similar to
those seen in pathological aging, the normal aging brain
changes are more subtle in nature despite resulting in
cognitive impairments. Differences in the molecular and
cellular changes between normal and pathological aging
will be discussed further below (Table 11.1).
11.4 mTOR SIGNALING PATHWAY
mTOR is a serine/threonine kinase, belonging to the
phosphatidyl inositol 30 kinase-related kinase family
[81]. It was named after its sensitivity to rapamycin, an
antifungal agent that is synthesized by the bacterial
species Streptomyces hygroscopicus [82]. The interaction
of rapamycin is an indirect interaction rather than a
direct one. Rapamycin forms a complex with cyclophi-
lin protein FKBP12, and this proteininhibitor complex
then binds to the FKBP12-rapamycin-binding (FRB)
domain of mTOR (Figure 11.3). This interaction inhibits
access to mTOR’s active site [8385]. mTOR homologs
have been identified in several non-vertebrate or non-
mammalian organisms including budding yeast [86,87],
C. elegans, Drosophila, and zebrafish [8890].
mTOR is found in two distinct protein complexes in
the cell: mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2). mTORC1 is composed of
mTOR, mLST8, DEPTOR, Raptor, AKT1S1/PRAS40,
and promotes transcription, translation, cell cycle pro-
gression, ribosome biogenesis, and cell growth through
repression of autophagy [91,92] (Figure 11.3). mTORC2
is composed of mTOR, mLST8, DEPTOR, Rictor,
mSin1 (also known as MAPKAP1), and PRR5 (also
known as PROTOR-1) [93,85] (Figure 11.3). mTORC2
regulates cell survival, cytoskeleton, cell cycle, and
cell metabolism [92]. Early evidence suggested that
rapamycin only inhibited the activity of mTORC1 but
not mTORC2, however chronic rapamycin treatment
has later been shown to inhibit mTORC2 through
binding to free mTOR [94]. mTOR interacts with Akt
in both complexes. mTORC1 is indirectly activated by
active Akt, whereas phosphorylation of Akt at Ser473
residue via mTORC2 upregulates the overall Akt/
mTOR pathway activity [95,96].
11.5 mTORC1
Deregulation of mTORC1 has been implicated in
aging, cancer, obesity, type 2 diabetes, and neurode-
generative diseases [97]. mTORC1 is activated in
response to nutrients, growth factors, oxygen, energy
status of the cell, and inflammation [93]. Active
mTORC1 in turn regulates eukaryotic translation and
protein synthesis through phosphorylation of S6 kinase
1 (S6K1) and eukaryotic translation initiation factor
4E (eIF4E) binding protein 1 (4E-BP1) [98,99]. eIF4E
normally binds to the m7GpppN cap located at the
50-end of mRNAs. Unphosphorylated 4E-BP1 represses
translation, and its phosphorylation via mTORC1
which causes dissociation of 4E-BP1 from eIF4E, and
enhances eIF4E-mediated translation. S6K1 regulates
protein synthesis, cell growth, and proliferation
through an mTORC1-dependent mechanism. mTORC1
phosphorylates and activates S6K1 [100,101]. Both S6K
and 4E-BP proteins contain a common amino acid
motif called TOR signaling (TOS) motif, which has
been suggested to be essential for interaction with
Raptor in mTORC1 [102,103].
Growth factors such as insulin and insulin-like growth
factor 1 (IGF1) activate receptor tyrosine kinases (RTKs).
Active RTKs induce production of phosphatidylinositol
(3,4,5)-trisphosphate (PIP3) and activate Akt. Akt exerts
its effect on mTORC1 through two mechanisms: inactivat-
ing the tuberous sclerosis complex (TSC) via phosphory-
lation, and inhibiting the interaction of the proline-rich
Akt substrate 40 kDa (PRAS40) with mTORC1.
When phosphorylated by Akt, PRAS40 can bind to
the 14-3-3 protein. Although the downstream events
initiated upon this binding are not clear yet, it has
been proposed that binding of the 14-3-3 protein
to phosphorylated PRAS40 inhibits it from binding to
mTOR, thus relieving inhibition on mTOR [104]. The
negative regulation of mTORC1 activity by PRAS40
might be due to inhibition of mTORC1-mediated
phosphorylation of 4E-BP1 and S6K1 [105,106].
TSC1 and TSC2, proteins upstream of mTOR identi-
fied as tumor suppressors, form heterodimers and act
in TSC to inhibit mTOR signaling by converting Ras
homolog enriched in brain (Rheb) from guanosine
triphosphate (GTP)-bound to guanosine diphosphate
(GDP)-bound forms. Rheb can only activate mTOR
when it is bound to GTP and farnesylated [107], hence
TSC indirectly inhibits mTOR signaling through
Rheb [108,109]. Akt phosphorylates TSC2, leading to
190 11. MAMMALIAN TARGET OF RAPAMYCIN (mTOR), AGING, NEUROSCIENCE, AND THEIR ASSOCIATION WITH AGING-RELATED DISEASES
III. mTOR IN MEMORY, BEHAVIOR, AND AGING
FIGURE 11.3 The mTOR signaling pathway. mTOR is found in two distinct protein complexes: mTORC1 and mTORC2. mTORC1 pro-
motes cell growth through a multistep process mediated by S6K, proliferation by relieving inhibition on eIF4G, lipid synthesis, lipogenesis,
and lipid metabolism by activating lipogenic transcription factors Lipin 1, SREBP-1, and PPARα. mTORC1 is also involved in ribosome bio-
genesis, adipogenesis, angiogenesis, and mitochondrial metabolism, and inhibits autophagic activity through inhibition of Atg1/Atg13/ULK
complex. mTORC2’s effects on these cellular processes are largely indirect, as mTORC2 exerts most of its effects through mTORC1 and its sig-
naling partners. mTORC1 in turn regulates the activity of mTORC2 through phosphorylation of mSin1 in the mTORC2.
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the disruption of the TSC1TSC2 heterodimer [110]
and relieves repression on mTOR. AMP-dependent
protein kinase (AMPK), on the other hand, is activated
by serine/threonine kinase LKB1/STK11-mediated
phosphorylation, and activates TSC2 in turn through
phosphorylation [111,112].
Recently, FKBP38 has been identified as another
component of mTORC1. FKBP38 binds to FRB domain
of mTOR, the binding site for another protein
belonging to the same family: fKBP12. However,
unlike FKBP12, FKBP38 does not need rapamycin to
bind mTOR. It has been also shown that Rheb-GTP
binds to FKBP38 with higher affinity than Rheb-GDP,
and active Rheb prevents FKBP38 from binding to
mTOR and relieving it from inhibition [113,114].
Yet another study suggested that the interaction of
Rheb with FKBP38 did not differ between GTP- or
GDP-bound forms [115].
An additional response mechanism of mTOR
to cytokines and growth factors has been suggested to
involve signal transducer and activator of transcription 3
(STAT3). Phosphorylation of STAT3 at Tyr705 by Janus
kinase or RTKs has been shown to facilitate dimerization
of STAT3 and the translocation of the dimer to the
nucleus. Upon nuclear translocation, STAT3 regulates
cell growth, proliferation, and cell survival [116].
Recently, phosphorylation of STAT3 at Ser727 by vari-
ous kinases including mTOR has been shown.
Furthermore, rapamycin was found to reduce phosphor-
ylated STAT3 levels [117], and loss of TSC1 and TSC2
has been linked to increased levels of phosphorylated
STAT3, a common observation in several human can-
cers. Elevated STAT3 activity promotes tumorigenesis
by positively regulating the expression of genes that are
involved in mechanisms crucial for cancer cells such as
cell growth, proliferation, survival, angiogenesis, and
metastasis [118].
mTORC1 also promotes tumorigenesis through
lipid synthesis, a mechanism required for actively
proliferating cells. mTORC1 positively regulates
sterol-regulatory-element-binding proteins (SREBPs),
transcription factors that control lipogenic genes and
their expression [119]. While mTORC1 induces nuclear
translocation of active SREBPs, inhibition of mTORC1
reduces SREBP expression at transcriptional and
translational levels [93]. The nuclear translocation of
SREBPs requires Lipin 1, a transcriptional coactivator
that is phosphorylated by mTORC1. Phosphorylated
Lipin 1 is translocated out of nucleus, and its exclusion
from the nucleus relieves SREBPs from suppression.
Free SREBPs then bind to target genes involved in
lipid synthesis [120].
Since growth factors and nutrients regulate adipose
tissue accumulation, it is not surprising that mTORC1
has a role in adipogenesis. Indeed, mTORC1 inhibition
has been shown to have severe effects on adipogenesis
and maintenance of adipose cells [93]. mTORC1 exerts
its positive effects on adipogenesis indirectly, through
peroxisome proliferator-activated receptor γ (PPARγ).
PPARγ controls expression of genes involved in fatty
acid synthesis and processing [121].
A related protein, PPARα, regulates genes that are
involved in hepatic ketogenesis and fatty acid
oxidation. Evidence suggests that mTORC1 inhibits
PPARα activity by recruiting its negative regulator,
nuclear receptor corepressor into the nucleus [122].
Interestingly, mTORC1 activity has been shown to be
increased in the livers of old mice [123], suggesting a
link between metabolism, aging, and mTORC1.
mTORC1 signaling has been shown to influence
proinflammatory processes and neo angiogenesis
through induction of hypoxia-inducible factor 1 α
(HIF1α) [124]. Cancer cells often have to cope with
oxygen deprivation, and HIF1α promotes expression
of genes that shift cellular energy metabolism from
aerobic to anaerobic respiration and regulates glycol-
ysis and glucose transport [125]. mTORC1 positively
regulates HIF1α through 4E-BP1-eIF4-dependent
translational activation. The HIF1αMTORC1 axis
is also involved in angiogenesis and promotes
tumorigenesis [93].
In addition to growth factors, amino acids are
crucial for activation of mTORC1. A recent study
proposed an inside-out model of amino acid sensing.
According to this model, amino acids accumulate in
the lysosomal lumen, and this accumulation initiates a
signaling cascade that involves vacuolar H1-adenoside
triphosphate ATPase (v-ATPase). The interaction of
v-ATPase with Ragulator at the lysosomal surface
recruits mTORC1 to the lysosome. Ragulator is a
protein complex that is essential for amino-acid-
dependent activation of mTORC1 [126]. The Ragulator
complex has guanine nucleotide exchange factor
activity on Rag GTPases, through which mTORC1 is
recruited to the lysosomal surface. Upon amino acid
stimulation, RagA or RagB, both Rag GTPases, inter-
acts with Raptor in mTORC1 [127]. This recruitment
allows mTORC1 to interact with Rheb since Rheb
resides at the lysosomal surface.
mTORC1 regulates cellular homeostasis in several
ways. One way is modulation of autophagy. Self-
degradation of proteins, and even entire organelles,
is achieved through formation of the autophagosome.
This process is crucial for clearance of damaged, dan-
gerous, or toxic particles from the cell. mTORC1 is a
known suppressor of autophagy. Studies in yeast and
mammals suggested that mTORC1 phosphorylates
autophagy-related proteins Atg1 and Atg13 found
in a complex that is essential for autophagosome
formation. Phosphorylation by mTORC1 disrupts
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the complex and inhibits the activation of the
autophagic pathway. In mammals, in addition to
Atg1 and Atg13 proteins, an Atg homolog named
ULK is negatively regulated by mTORC1, indicating
a conserved mechanism for mTORC1-mediated
regulation of autophagy [128].
Finally, lysosome biogenesis and its modulation by
the mTORC1TFEB (transcription factor EB) axis
is an important regulator of cellular homeostasis.
Lysosomes are responsible for lipid homeostasis, clear-
ance of proteins and organelles, energy metabolism,
stress response, and pathogen defense [129]. mTORC1
is one of the key molecules regulating TFEB, which in
turn promotes formation of autophagosomes and their
fusion with lysosomes [130]. Phosphorylation of TFEB
by mTORC1 upon activation of the nutrient-sensing
pathway, allows 14-3-3 protein to bind TFEB and
inhibit it from translocating to the nucleus. As
lysosomal dysfunction is implicated in aging and
age-related diseases, such as cancer and neurodegen-
eration, inhibition of mTORC1 is considered as a
potential therapeutic approach [93].
11.6 mTORC2
In contrast to substantial evidence emerging on the
signaling cascades involving mTORC1, less is known
about upstream and downstream components of the
mTORC2 signaling cascade. It is known that mTORC2
is insensitive to nutrients or energy status of the cell
but sensitive to growth factors and insulin [131].
Insulin has been suggested to facilitate mTORC2
binding to ribosome through a poorly understood
PI3K-dependent mechanism [132]. Recent evidence
suggests an interplay between mTORC1 and mTORC2
in response to insulin stimulation, and their regulatory
role in insulin receptor substrate 1 (IRS-1) degra-
dation through growth factor receptor-bound protein
10-dependent mechanism [133,134]. When active,
mTORC2 is involved in cell survival, cytoskeleton
organization, and cellular metabolism [97].
The best-characterized role of mTORC2 is
phosphorylation of Akt at the Ser473 residue, a post-
translational mechanism required for full Akt activa-
tion [96]. This mTORC2-dependent phosphorylation of
Akt links mTORC2 to the mTORC1 signaling pathway.
However, studies in which mTORC2 is knocked out or
knocked down suggest that mTORC2 function is not
essential for mTORC1 activity [135]. mTORC1 might
indirectly inhibit mTORC2 activity through phosphor-
ylation of mSin1 by S6K1 [136]. Other substrates of
mTORC2 are identified as serum- and glucocorticoid-
induced protein kinase 1, protein kinase C (PKC)
isoforms (in particular, PKCα). The former is involved
in ion transport and cell growth, while the latter links
mTORC2 to cytoskeleton organization [97].
As we have mentioned earlier, recent studies
provide evidence of the inhibition of mTORC2 activity
upon long-term rapamycin treatment. A model involv-
ing dephosphorylation of mTORC2 components mSin1
and Rictor, and subsequent dissociation of mTORC2
in response to rapamycin was proposed to explain
rapamycin’s inhibitory effect on mTORC2 [137].
Similar to mTORC1, the TSC1TSC2 heterodimer was
found to be associated with mTORC2. However, this
interaction was independent of Rheb, indicating
distinct regulatory mechanisms acting on both mTOR
complexes. Furthermore, while TSC has an inhibitory
effect on mTORC1, it activates mTORC2 [138]. Some
recent studies propose the association of mTORC2
with ribosomes, and an endoplasmic reticulum (ER)
subcompartment called mitochondrial-associated ER
membrane (MAM) in response to growth factor stimu-
lation. It seems that mTORC2 is required for main-
tenance of MAM, regulation of mitochondrial
metabolism and cell survival, although these claims
remain to be further explored [132,139,140].
11.7 mTOR SIGNALING AND AGE-
RELATED DISEASES
The main focus in the last decade has been on
mTOR and its relationship to lifespan and disease
prevention. It is clear from a large amount of evidence
that mTOR overactivation promotes aging and disease,
which in turn reduces lifespan [97]. By contrast, block-
ing mTOR retards aging and disease progression, and
significantly increases lifespan. Less work has been
performed about the role of mTOR in brain aging and
disease but evidence from the role mTOR signaling
plays in non-neurological disorders indicates that it
could alter the course of normal and pathological
brain aging.
11.7.1 mTOR and Metabolic Diseases
The mTOR signaling pathway is a nutrient-sensing
pathway, meaning that it is regulated by nutrients
and several other stimuli, and when activated, it
influences cellular processes that have vast effects
from metabolism to growth and cellular survival to
aging [97]. Owing to its close relation with metabolic
processes, mTOR is involved in several metabolic
diseases, including diabetes mellitus. Diabetic compli-
cations, such as insulin resistance, have been linked
with overactivation of the mTOR pathway [124].
Overactivated mTOR has been shown to cause insulin
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resistance, partly due to activation of S6 kinase (S6K)
via active mTOR and subsequent degradation of
IRSs. This feedback loop renders insulin signaling
impaired [134].
In relation to diabetic complications, the mTOR
signaling pathway has also been shown to regulate
pancreatic β-cell proliferation and total β-cell mass
[141]. Progressive pancreatic β-cell loss is a common
characteristic of type 1 and type 2 diabetes [142].
Inhibition of mTORC1 via rapamycin treatment only
abolished glucose-stimulated β-cell expansion, but not
lipid-induced expansion in zebrafish. The latter has
been shown to require insulin/IGF1 signaling, and in
combination with the mTOR pathway, they exerted
their nutrient-sensing effects that promote pancreatic
β-cell neogenesis. These findings suggested a distinct
role for mTOR signaling in progression of diabetes
and diabetic complications [143].
The vascular endothelial dysfunction and its most
common consequence, cardiovascular diseases, are
associated with advancing age. In one study, arteries
of older mice, which displayed endothelial dysfunc-
tion, have been shown to harbor increased mTOR
signaling. SIRT-1, AMPK-1, and mTOR signaling
pathways have been shown to be linked to the
vascular aging phenotype and several studies suggest
that their convergence and crosstalk rather than their
independent activities affect vascular endothelial cells.
Inhibition of mTOR by rapamycin or rapamycin
analogs such as life-long caloric restriction (CR)
prevents increased arterial mTOR signaling, improves
nitric oxide amounts and ergo, prevents endothelial
dysfunction in old mice [144].
11.7.2 mTOR and Cancer
There is emerging evidence that cancer is an age-
related disease, and reduced or delayed carcinogenesis
is associated with slow, healthy aging. The incidence
of common cancers, such as lung, colon, breast, pros-
tate, pancreatic, thyroid, gastric, and brain, increases
with age. Not surprisingly, people who live more than
90 years are protected from cancer. Furthermore, a
similar pattern has been shown in several animal
models such as mice and rats. In long-lived mice and
rats, cancer prevalence is very low despite high levels
of oxidative stress [145].
The PI3K/Akt/mTOR pathway is among the most
frequently altered pathways in human cancers. This
may be due to its control over processes that are
crucial for tumorigenesis, such as cell cycle progres-
sion, cell survival, cellular metabolism and energetics,
and transcription [146]. Activation or aberrant
functioning of the mTOR pathway by either activation
of oncogenes such as Ras, Raf, MEK, PI3K, and Akt or
loss of tumor suppressors such as PTEN, NF-1, and
P53 has been reported by several research groups
studying human cancers [147,128,148,149]. Mutations
in the genes encoding the proteins involved in this
pathway have been implicated in various cancers.
Although mutations that have been identified affect
upstream elements such as PTEN [150], PIK3CA [151],
PIK3R1 [152] and Akt [153], rather than directly
targeting mTOR, aberrant functioning of this pathway
is clearly involved in cancer development, and
particularly in ovarian cancer [146].
There are several aspects of tumorigenicity on
which mTOR has direct or indirect effects. The
mechanism through which mTOR is acting is transla-
tion initiation, which is required for normal cell
growth and proliferation. When aberrant, transla-
tional control leads to uncontrolled growth of the
cell. Eukaryotic translation initiation is regulated by
eukaryotic initiation factors eIF4G, eIF4E, eIF4A, and
eIF4F. Of these, eIF4E is regulated by inhibitory
eIF4E binding proteins (4E-BPs). 4E-BPs mainly act
via binding to eIF4E and inhibiting its association
with eIF4F, and therefore lowering translation levels.
However, when phosphorylated by active mTOR in
the mTORC1 complex upon mitogenic stimulation,
4E-BP1 dissociates from eIF4E, allowing it to form
the translation initiation complex and proceed with
the translation process [154156].
Growth factors such as insulin and nutrients regulate
mTORC1 activity via activation of the PI3K/Akt
pathway [128], and the overexpression of growth factor
receptors such as insulin-like growth factor receptor
and human epidermal growth factor receptor 2 may
activate the PI3K/Akt and mTOR pathways [157].
mTORC2, on the other hand, affects tumorigenesis
through its role in glucose metabolism, organization of
the actin cytoskeleton, and apoptosis in addition to its
distinct role in cell growth and proliferation [96,158].
A subunit of mTORC2, Rictor, is overexpressed in some
cancer types. Rictor overexpression leads to overactive
mTORC2 activity, which has been shown to be associ-
ated with higher proliferative and invasive potential
of tumors [159,160]. TSC1 or TSC2 mutations, on the
other hand, cause tuberous sclerosis, a familial cancer
syndrome which leads to benign tumors but may
progress to malignant ones [161].
The close relationship between mTOR, aging, and
cancer may be based on the phenomenon called gero-
conversion. In proliferating cells, cellular growth and
cell division are balanced in response to nutrients and
growth factors. In aging cells, the mTOR pathway
shifts from cellular arrest and quiescence into senes-
cence. In neoplasms and cancers, cellular senescence
is overcome and cells start dividing uncontrollably.
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Hence, both mechanisms depend partly on how the
mTOR pathway acts and how it is regulated [145].
11.7.3 mTOR Signaling and Normal
and Pathological Brain Aging
mTOR is expressed at high levels in the brain,
mainly in neurons but also in glial cells. It plays an
important role in development for neuron survival
and growth. In the adult brain, mTOR controls synap-
tic plasticity and processes that underlie learning and
memory [162]. For example, increases in GluR1 levels
were shown to be necessary in the dorsal hippocam-
pus of rat for the learning and memory consolidation
process around an inhibitory avoidance training and
3 h after the training. This study also demonstrated
that the increase in the level of GluR1 was obtained
through the BDNF/mTOR signaling pathway [163].
mTOR contributes to changes in LTP by regulating
protein synthesis in the adult brain [162]. Thus, in
normal conditions mTOR is necessary for brain
function. However, during normal and pathological
aging, mTOR signaling may underlie some of the
deficits in brain areas controlling learning and memory
(Table 11.1).
In terms of normal brain aging, manipulations of
the mTOR pathway result in ameliorating effects
against age-related decline. It has been shown that
partial inhibition of the mTOR pathway by rapamycin
extends lifespan in many model organisms. However,
another crucial issue is whether this lifespan increase
is correlated with preserved cognitive functions in old-
er ages which would normally decline. Studies in
mouse models indicate that rapamycin treatment
starting at younger ages has an enhancing effect on
spatial memory and learning in older ages. It was
shown that these ameliorating effects of rapamycin are
associated with reduced IL-1β, which is a proinflam-
matory cytokine associated with memory impairments
in older adults’ levels in the hippocampus, and
increased NMDA signaling. However, these enhancing
effects on learning and memory are not observed if the
rapamycin treatment starts at older ages [164]. Another
study indicated that partial and chronic inhibition of
mTOR by rapamycin ameliorated both the cognitive
and non-cognitive components of behavior in a mouse
model. Eight-month-old animals treated with rapamy-
cin showed better performance in terms of spatial
learning-memory; and 25-month-old animals treated
with rapamycin showed better long-term memory
performance, which is related to aversive stimuli
when they are compared with non-treated controls.
Additionally, non-cognitive components of behavior,
such as anxiety and depressive behaviors, which
are also observed in older populations, are reduced
in rapamycin-treated groups. The mechanism through
which this reduction is occurring is thought to
be mediated by partial inhibition of mTOR, which
results in increased major monoamine levels includ-
ing epinephrine, norepinephrine, dopamine, and
5-hydroxytryptamine [165]. In conclusion, the data
indicate that in the normal aging condition, that is,
without pathology, partial inhibition of mTOR could
improve cognitive decline and have ameliorating
effects on cognitive and non-cognitive components
of behavior that decline with normal aging.
To date, more information has been obtained with
respect to the mTOR signaling pathway and patholog-
ical brain aging. In terms of normal brain aging,
several reports suggest that a decreased rate of
hippocampal neurogenesis has been associated with
cognitive impairment in the elderly, in particular with
the learning and memory processes [166]. In the past
it was thought that neurons do not regenerate,
however, it is clear now that neural stem and/or
progenitor cells with the capacity to generate new
neurons throughout the lifespan have been found in
certain regions of the adult mammalian brain [167].
The fate of hippocampal neural stem cells depends on
both the internal signaling pathways and external sti-
muli, such as growth factors and nutrients [168,169].
Different subtypes of neural stem cells are affected
differentially by aging. For instance, the number of
quiescent hippocampal neural stem cells has a slower
rate of decay than the active hippocampal neural stem
cells. Although some reports suggest that the total
number of hippocampal neural stem cells does not
decline with age but rather the number of quiescent
hippocampal neural stem cells increases in response
to the aging process [170,171], another study showed a
significant decline in the number, and the proliferation
rate of hippocampal neural stem cells in aging mice.
Interestingly, the mTOR signaling pathway activity
was shown to be impaired in these cells, and its resto-
ration stimulated the proliferation of hippocampal
neural stem cells in the aged mouse brain.
Furthermore, inhibition of the mTOR pathway was
shown to be sufficient to induce premature aging in
the young mice [172].
11.7.4 Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative
disease which is characterized by progressive dopami-
nergic neural loss, especially in substantia nigra pars
compacta, and it results in deficits in motor functions
including tremors and ataxia [173]. Currently, there
is no decisive treatment for PD; one reason is that
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underlying pathology and the etiology of PD are
not very well known. However, current studies
have revealed associations of neural loss in PD with
apoptosis, oxidative stress, DNA damage, mitochon-
drial dysfunction, aberrant protein aggregation, and
endoplasmic reticulum stress [174176].
Interestingly, studies have also suggested that
components of the mTOR pathway could play a role in
PD progression and manipulations targeting this
pathway may promise therapeutic strategies for PD
(Table 11.1). It has been shown that treatment with
rapamycin, which is the pharmacological inhibitor
of mTOR, suppresses the PD-related pathological
phenotype, including muscle degeneration, locomotor
activities, and mitochondrial defects, and these effects
of rapamycin were mediated by 4E-BP activity in the
Drosophila melanogaster model of PD [177]. In contrast,
it was reported that in vitro models of PD, in which
PD was induced by specific toxins, inhibited mTOR
activity. In this model inhibited mTOR activity, which
is related to increased AMPK and decreased Akt
activity, was associated with neural loss [178]. Based
on these studies, it may be the case that both inhibition
and activation of the mTOR pathway could be associ-
ated with PD-related neural death. Another study
indicated that selective suppression of the mTOR
pathway is protective against PD-related neural death,
and it was shown that although rapamycin is an
inhibitor of mTOR activity, it spares some activity of
mTOR, such as regulation of Akt phosphorylation,
while it inhibits other mTOR activities like S6K (also
known as p70S6K) activation. Also, in this study when
all the actions of mTOR were inhibited, dephosphory-
lation of Akt and neural death were induced in both
in vitro and mouse models of PD [179]. Therefore for
PD, it could be argued that some activities of mTOR
are essential for the survival of the neurons and others
could be harmful for the neurons during the disease
progression. Moreover, complete inhibition of mTOR
activity may not be protective against neural death in
PD, as the protective effect of rapamycin is associated
with its selective suppression of mTOR activity.
11.7.5 Alzheimer’s Disease
Another pathology associated with advanced age is
Alzheimer’s disease (AD). AD is the most common pro-
gressive neurodegenerative disease in the aging popula-
tion; cognitive deficits can be observed across domains
like memory, spatial learning, language, attention, visual
perception, executive functions, and social function
[180]. Progressive amyloid-beta protein accumulation
and presence of neurofibrillary tangles with hyperpho-
sphorylated tau protein are the pathological hallmarks
of AD, and they are associated with progressive neural
loss [181]. One reason for the accumulation of these
harmful proteins that has been proposed is the
presence of an altered autophagy response against
these toxic substances in the affected cells [182].
Moreover, since there is an established relationship
between the mTOR pathway and autophagy, the
mTOR pathway has become a target for interventions
and manipulations in order to understand its role in
AD (Table 11.1). Evidence demonstrates that long-term
inhibition of mTOR with rapamycin in the transgenic
AD mouse model reduces and prevents AD-like cogni-
tive deficits; rapamycin-treated transgenic mice show
better performance in spatial memory and learning
tasks. This inhibition lowers the levels of amyloid-beta
protein (Aβ42) and prevents or delays the onset of AD.
Also, it has been shown that autophagy is induced in
the hippocampus of rapamycin-treated transgenic
mice. However, these ameliorating effects could not be
found in wild-type mice treated with rapamycin, hence
the effects of rapamycin may depend on the endoge-
nous Aβ levels in mice [183]. In another study, mTOR
was inhibited by rapamycin in 2- and 15-month-old
transgenic AD model mice. In 2-month-old mice, this
inhibition prevented cognitive decline in learning
and memory, increased autophagy, and decreased
the levels of Aβ, tau, and tangle accumulation by
increasing the soluble Aβ and tau levels, whereas in
15-month-old mice, this inhibition did not change the
soluble or non-soluble levels of Aβ and tau and did
not ameliorate cognitive deficits [184]. Taken together,
inhibition of mTOR via rapamycin could ameliorate
the progression of AD and AD-related cognitive
deficits, but the extent of these effects may depend on
the AD progression.
11.7.6 Frontotemporal Dementia
Frontotemporal dementia is an age-related
neurodegenerative disease characterized by neural
loss in frontal and temporal lobes (Figure 11.1).
Clinical manifestations of frontotemporal dementia in
response to neural loss in these specific regions are
observed as alterations of certain personality traits.
These alterations include abnormal social behavior
and apathies, and cognitive deficits in executive
function, attention, visuospatial abilities, language,
and memory [185]. The molecular and cellular
alterations underlying the neural loss are related to
proteinopathies, which refers to the presence of
malformed or abnormal proteins. One of the proteins
associated with frontotemporal dementia is TDP-43.
TDP-43 is a DNA/RNA-binding protein, found in the
cytoplasmic ubiquitin inclusions of the affected cells,
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and plays a role as a main component in the disease
progression [186].
Since the neurodegeneration process in frontotem-
poral dementia is associated with proteinopathies,
induction of autophagy in the affected cells has
become a focus as a possible intervention. Studies
conducted in the mouse model of frontotemporal
dementia demonstrated that inhibition of the mTOR
pathway by rapamycin prevents motor and cognitive
deficits including learning and memory declines,
reduces the neural loss and the caspase-3 levels, which
is the indicator of the neural death, and decreases
levels of TDP-43 products [187] (Table 11.1). Therefore,
it is likely that the inhibition of mTOR, which might
result in autophagy activation, may be a promising
therapeutic approach for age-related neurodegenera-
tive diseases with proteinopathies.
11.7.7 Huntington’s Disease
Huntington’s disease (HD) is an inherited neurode-
generative disease affecting the whole brain, yet some
regions, such as the basal ganglia and hippocampus,
are more vulnerable. Clinical symptoms include motor
dysfunction, muscle rigidity, problems in memory and
executive functions, anxiety, and depression. HD is a
polyglutamine tract disorder, emerging when the
number of CAG repeats in the HTT gene encoding
Huntingtin protein exceeds a specific threshold and
mutant Huntingtin protein, which has toxic effects, is
produced [188]. Alterations due to mutant Huntingtin
protein expression are decreased uptake of glutamate
and increased NMDA receptor signaling at the striatal
excitatory synapses. Decreased levels of BDNF, and
altered striatal dopamine and endocannabinoid
signaling accompany degeneration in HD [189].
As in the cases of AD and frontotemporal dementia,
abnormal protein aggregation has been observed in
HD. Thus, activation of autophagy through the mTOR
pathway could have therapeutic effects in HD. In vitro
studies conducted with HD models indicated that
inhibition of mTOR with small molecule enhancers of
rapamycin increased the clearance of the mutant
Huntingtin fragments in the affected cells (Table 11.1).
Another study using the Drosophila melanogaster model
of HD demonstrated that these small molecule
enhancers of rapamycin protect against toxicity
induced by mutant Huntingtin protein [190]. Other
studies in Drosophila melanogaster have supportive
findings of rapamycin protection against neural death
and toxicity associated with HD, and studies with a
mouse model of HD showed that rapamycin treatment
reduces the HD-related motor and behavioral deficits
and decreased protein aggregation [191]. It could be
said that interventions like the rapamycin targeting of
mTOR and the autophagy mechanism could be a
promising therapeutic approach and area of research
for HD.
11.8 INTERVENTIONS FOR ALTERING
mTOR ACTIVITY
It has been previously mentioned throughout this
chapter that rapamycin treatment, which inhibits
mTOR, can alter the course of aging-related diseases
and pathologies. Moreover, it appears to have beneficial
effects on lifespan and some of the declines associated
with aging. There are many studies reporting that
rapamycin treatment extends lifespan in various
organisms. For instance, rapamycin treatment late in
life (at 600 days of age) extended lifespan in both male
and female genetically heterogeneous mice [192].
Another study in Drosophila suggested that genes
encoded by mitochondrial DNA have influence on the
mTOR pathway, and that mTOR inhibition
via rapamycin increases mitochondrial respiration and
decreases H2O2 production [193]. Similar studies
in yeast suggested reduced TOS due to deletion of
TOR1 gene or rapamycin treatment, and modulation
of reactive oxygen species by enhancement of the
mitochondrial respiration as a possible mechanism for
lifespan extension [194,195].
Rapamycin treatment has also been shown to
prevent age-related metabolic diseases including
obesity [196,197] and diabetic complications such as
retinopathy, nephropathy, and coronary disease in
animal models and humans [198,196,199]. Rapamycin
mimics starvation or CR, depending on the adminis-
tered concentration. Therefore, it tricks the organism to
think that nutrient supply is growing short. Starvation
has several metabolic effects including increased
gluconeogenesis, ketogenesis, lipolysis, decreased insulin
levels, and it leads to insulin resistance [200].
Given the fact that mTOR signaling is almost
universally activated in cancer, rapamycin, rapamycin
analogs (i.e., rapalogs), and dietary regimens such as
CR have become promising approaches in cancer
prevention and treatment [201203]. Rapalogs, such as
temsirolimus and everolimus, are being used as
anticancer drugs, the former being the first rapalog
approved by FDA for use in humans [204,205].
Although rapalogs are currently being used in numer-
ous clinical trials, their role as anticancer agents
remains modest. This modest effect may be due to
their lack of toxicity, and hence inability to kill cancer
cells at relevant concentrations. Rather, they act to
slow down the growth of cancer cells and prove
more effective when used in combination with other
anticancer drugs. Regardless of their disadvantage as
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anticancer drugs, they are still effective agents for
cancer-preventive and antiaging purposes.
Another intervention that may be beneficial is CR,
which is thought to act by blocking the mTOR pathway
in a manner similar to rapamycin treatment. Even
short-term (i.e., 8 weeks) CR had a protective effect on
renal cells of the aged rats. Reduced mitochondrial
oxidative damage, retardation of renal senescence, and
increased autophagic activity have been accompanied
by decreased mTOR levels, and increased SIRT-1 and
AMPK levels, in these old rats [206]. Of these mechan-
isms, autophagic activity has particular significance
since its decrease during aging has been considered as
the underlying mechanism for the accumulation
of abnormal/damaged macromolecules. Degradation of
long-lived proteins, unfolded or incorrectly folded
proteins, and damaged organelles occur through autop-
hagic pathways. Hence, it is essential for maintenance
of cellular and organismal homeostasis [207209].
It is important to point out that both rapamycin and
CR have been shown to affect males and females
differentially. In one study, tissue- and sex-specific
effects of rapamycin on the proteasome-chaperone
network have been shown [80]. For instance, levels of
proteasome-related chaperones increased more in
females than males. Furthermore, brains of rapamycin-
treated females had higher levels of mTOR pathway
proteins (p-mTOR, p-Akt, rpS6, and 4E-BP1), than
males and other tissues tested. These results suggest
that rapamycin increases proteasome activity in the
brains of female mice, compared to other tissues and
male counterparts.
Another study showed that short-term CR in male
mice shifted the gene expression profile toward a more
feminine type. In this microarray-based study, CR has
been shown to change expression levels of over 3000
genes involved in hormone signaling, aging, cell cycle,
and apoptosis [210]. When the overall life expectancy
of males and females is taken into account, i.e., that
females of most mammals have a longer lifespan than
males, these results seem quite explanatory for both
the underlying mechanisms for CR-induced longevity
and sex-dependent variations in response to CR and
CR mimetics.
Taken altogether, rapamycin, rapalogs, and CR have
been shown to have positive effects on various
age-related diseases, and to extend overall and healthy
lifespan in both animals and humans. Thus, the effects
of CR and the CR-mimetic rapamycin on lifespan
have been the subject of ongoing research. It will be
important to determine the best regimen, either dietary
or therapeutic drug dose, for the optimal antiaging
effects. Moreover, more research needs to be per-
formed to determine the exact effects of CR and CR
mimetics on normal brain aging.
11.9 CONCLUSION
Normal aging is accompanied by a range of biologi-
cal changes, many of which diminish the quality of
life and interfere with the ability of the elderly to
function unassisted in society. Even in the absence
of evident pathology, cognitive function declines
during old age and is often reflected as a significant
loss of learning and memory ability. Undoubtedly, the
biological changes are multifactorial in nature,
and are likely caused by a combination of genetic and
environmental factors. Nevertheless, understanding
the contribution of individual factors to age-related
changes in cognitive function would provide important
insight into the mechanisms by which such changes
occur, as well as suggest strategies for preventing
or ameliorating cognitive changes.
The mTOR pathway appears to be a very important
target for altering the course of aging-related cognitive
decline and diseases that are both neurological and
non-neurological in nature. Understanding the exact
effects of mTOR on aging as well as the appropriate
therapeutic approaches is the subject of ongoing
research. Undoubtedly, these data will contribute to
our understanding of both normal and pathological
aging and how it can be prevented or altered.
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Terman A. Autophagy and aging: the importance of maintain-
ing “clean” cells. Autophagy 2005;1:13140.
[208] Levine B, Klionsky DJ. Development by self-digestion: molecu-
lar mechanisms and biological functions of autophagy. Dev
Cell 2004;6:46377.
[209] Rajawat YS, Hilioti Z, Bossis I. Aging: central role for autop-
hagy and the lysosomal degradative system. Ageing Res Rev
2009;8:199213.
[210] Estep PW, Warner JB, Bulyk ML. Short-term calorie restriction
in male mice feminizes gene expression and alters key regula-
tors of conserved aging regulatory pathways. PLoS One
2009;4:e5242.
203REFERENCES
III. mTOR IN MEMORY, BEHAVIOR, AND AGING
